4DMT's gene ther­a­py re­duced need for stan­dard-of-care in­jec­tions to treat age-as­so­ci­at­ed vi­sion loss

4D Mol­e­c­u­lar Ther­a­peu­tics’ one-time gene ther­a­py re­duced the need for an­nu­al in­jec­tions in pa­tients with age-re­lat­ed blind­ness in a mid-stage tri­al.

The com­pa­ny on Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER